Profile | GDS2987 / GI_13470093-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | ||
GSM215244 | HMVEC_vehicle_rep2 | 16.1 | 39 |
GSM215253 | HMVEC_vehicle_rep3 | ||
GSM215254 | HMVEC_atorvastatin_rep1 | ||
GSM215282 | HMVEC_atorvastatin_rep3 | ||
GSM215344 | HMVEC_atorvastatin_rep2 | ||
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 52 | 66 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | ||
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 26.7 | 41 |
GSM215294 | HMVEC_SLx2119_rep1 | 4.8 | 18 |
GSM215295 | HMVEC_SLx2119_rep2 | 34.1 | 55 |
GSM215296 | HMVEC_SLx2119_rep3 | 14.4 | 24 |
GSM215297 | PASMC_vehicle_rep1 | ||
GSM215298 | PASMC_vehicle_rep2 | 19.3 | 30 |
GSM215310 | PASMC_vehicle_rep3 | ||
GSM215311 | PASMC_atorvastatin_rep1 | 22.6 | 37 |
GSM215312 | PASMC_atorvastatin_rep2 | 19.5 | 30 |
GSM215313 | PASMC_atorvastatin_rep3 | ||
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | ||
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 22.6 | 40 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 6.4 | 12 |
GSM215327 | PASMC_SLx2119_rep1 | ||
GSM215328 | PASMC_SLx2119_rep2 | 44.3 | 60 |
GSM215329 | PASMC_SLx2119_rep3 | 3.1 | 6 |
GSM215330 | Fibroblasts_vehicle_rep1 | ||
GSM215331 | Fibroblasts_vehicle_rep2 | 13.6 | 36 |
GSM215332 | Fibroblasts_vehicle_rep3 | 6.7 | 23 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | ||
GSM215334 | Fibroblasts_atorvastatin_rep2 | 15 | 39 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | ||
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | ||
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | ||
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | ||
GSM215339 | Fibroblasts_SLx2119_rep1 | 10.3 | 30 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 10 | 28 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 10.1 | 26 |